Epidemiology and Burden of Illness of Lennox-Gastaut Syndrome in Taiwan: A Retrospective Cohort Study
Authors:
- Avery Shuei-He YangAYAvery Shuei-He Yang
- Daniel Hsiang-Te TsaiDaniel Hsiang-Te Tsai
- Li-Wen ChenLCLi-Wen Chen
- Chu Chiao WangCWChu Chiao Wang
- Shih-Chieh ShaoSSShih-Chieh Shao
- Wendy Wenjie SongWSWendy Wenjie Song
- Mahsa H KouhkamariMKMahsa H Kouhkamari
- Wei-Ching HuangWHWei-Ching Huang
- Sally BowditchSBSally Bowditch
- Edward Chia-Cheng LaiEdward Chia-Cheng Lai
Open Access
- 1 September 2025
- journal article
- research article
- Published by Taylor & Francis in Risk Management and Healthcare Policy
- Vol. ume 18, 3153-3166
Abstract
Purpose: Examine the epidemiology and burden of illness of patients with Lennox-Gastaut syndrome (LGS) in Taiwan. Methods: The National Health Insurance Database (NHID) was used, complemented by the Chang Gung Research Database (CGRD). Confirmed LGS was defined by International Classification of Diseases-10 (ICD-10) LGS codes or ≥ 1 rufinamide prescription; probable LGS was defined as patients aged ≤ 10 years when receiving ≥ 3 antiseizure medications (ASMs), with ICD-9/10 codes for developmental delay. Independent clinical review/validation of all LGS cases in the CGRD was conducted. Prevalence, incidence, time to treatment/LGS diagnosis, hospitalizations, costs (US dollars), ASM usage, and mortality were assessed. For the NHID, a positive predicted value (PPV) was calculated from the CGRD validation step to adjust prevalence/incidence estimates. Results: In the NHID, 190 patients with confirmed LGS were identified. In 2018, PPV-adjusted prevalence was 2.4, 0.6, and 10.2 per 100,000 people and PPV-adjusted incidence was 0.6, 0.2, and 2.4 per 100,000 person-years in the total, adult, and pediatric populations, respectively. Of 92 (48%) hospitalized patients, 22 (24%) had ≥ 3 hospitalizations/year. Mean (standard deviation [SD]) time to treatment and LGS diagnosis were 12.3 (26.5) and 110.1 (54.7) months. Mean length of stay was around 12 days. Most hospitalizations (96%) were epilepsy related. Mean (SD) hospitalization cost was $237 ($216) per day. Mean (SD) total inpatient and outpatient costs were $5800 ($817) and $2667 ($132), respectively, per patient per year (PPPY); medication in hospital and ASM costs were $1910 ($108) and $1614 ($93) PPPY. Most prescribed ASMs were valproate (89%), levetiracetam (83%), clonazepam (69%), clobazam (68%), and topiramate (65%). Mortality was 0.01 deaths per 100,000 people in 2018. Conclusion: Although prevalence and incidence of LGS in Taiwan were lower than in other countries, the multifaceted burden of illness in LGS is highlighted herein. Reduced hospitalizations through better epilepsy control may reduce LGS expenditure.Keywords
This publication has 48 references indexed in Scilit:
- Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKDJAMA Network Open, 2024
- Discharge status validation of the Chang Gung Research database in TaiwanBiomedical Journal, 2022
- Analysis of trends and factors determining initial antiseizure medication choice for epilepsy in TaiwanSeizure: European Journal of Epilepsy, 2021
- Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort studySeizure: European Journal of Epilepsy, 2021
- The Chang Gung Research Database—A multi‐institutional electronic medical records database for real‐world epidemiological studies in TaiwanPharmacoepidemiology and Drug Safety, 2019
- Burden of illness in patients with possible Lennox–Gastaut syndrome: A retrospective claims-based studyEpilepsy & Behavior, 2018
- Lennox-Gastaut syndrome: a comprehensive reviewNeurological Sciences, 2017
- Chang Gung Research Database: A multi-institutional database consisting of original medical recordsBiomedical Journal, 2017
- Assessment of treatment patterns and healthcare costs associated with probable Lennox–Gastaut syndromeEpilepsy & Behavior, 2017
- Impact of Lennox-Gastaut Syndrome (LGS) on health-related quality of life (HRQL) of patients and caregivers: Literature reviewSeizure: European Journal of Epilepsy, 2009